Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFFIRM-AHF
NL-OMON49709Phase 4Active, not recruiting
- Sponsor
- CSL Vifor
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Acute Heart Failure (AHF) and iron deficiency anemia (IDA) comparing Intravenous ferric carboxymaltose with Placebo (2 arms). Primary endpoint: Composite of recurrent heart failure hospitalizations and cardiovascular death. Started Jun 2017; status: active, not recruiting.
02
Drugs
ferric carboxymaltose
03
Conditions
Acute Heart Failure (AHF)iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NL-OMON49709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49709.